SENORES

Senores Pharmaceuticals Share Price

₹494.90 -15.25 (-2.99%)

22 Jan, 2025 12:35

SIP TrendupStart SIP in SENORES

Start SIP

Performance

  • Low
  • ₹490
  • High
  • ₹513
  • 52 Week Low
  • ₹435
  • 52 Week High
  • ₹610
  • Open Price₹510
  • Previous Close₹510
  • Volume187,742

Investment Returns

  • Over 1 Month + 26.57%
  • Over 3 Month + 26.57%
  • Over 6 Month + 26.57%
  • Over 1 Year + 26.57%
SIP Lightning

Smart Investing Starts Here Start SIP with Senores Pharmaceuticals for Steady Growth!

Invest Now

Senores Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 2,279
  • P/B Ratio
  • 7.5
  • Average True Range
  • 32.25
  • EPS
  • 6.84
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • 40.4
  • MFI
  • 60.55

Senores Pharmaceuticals Financials

Senores Pharmaceuticals Technicals

EMA & SMA

Current Price
₹494.90
-15.25 (-2.99%)
pointer
  • stock-down_img
  • Bearish Moving Average 5
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • -
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

514.48 Pivot Speed
  • R3 549.67
  • R2 539.38
  • R1 524.77
  • S1 499.87
  • S2 489.58
  • S3 474.97

What's your outlook on Senores Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

N/A

Group Rank

Senores Pharmaceuticals develops and manufactures niche, complex, and specialty pharmaceutical products adhering to international quality standards. With a global focus, the company is committed to innovation, affordable healthcare, and meeting the evolving demands of the healthcare industry.

Senores Pharmaceuticals Ltd has an operating revenue of Rs. 264.03 Cr. on a trailing 12-month basis. An annual revenue growth of 457% is outstanding, Pre-tax margin of 12% is healthy, ROE of 15% is good. The company has a debt to equity of 65%, which is bit higher. The stock from a technical standpoint is trading close to its key moving averages, around -0% and -0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 74 which is a FAIR score but needs to improve its earnings, a RS Rating of 33 which is POOR indicating the underperformance as compared to other stocks, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Senores Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-23 Quarterly Results & Others To consider other business matters.

Senores Pharmaceuticals F&O

Senores Pharmaceuticals Shareholding Pattern

45.76%
4.99%
3.96%
4.25%
0.01%
28.71%
12.32%

About Senores Pharmaceuticals

  • NSE Symbol
  • SENORES
  • BSE Symbol
  • 544319
  • Managing Director
  • Mr. Swapnil Jatinbhai Shah
  • ISIN
  • INE0RB801010

Similar Stocks to Senores Pharmaceuticals

Senores Pharmaceuticals FAQs

Senores Pharmaceuticals share price is ₹494 As on 22 January, 2025 | 12:21

The Market Cap of Senores Pharmaceuticals is ₹2279.2 Cr As on 22 January, 2025 | 12:21

The P/E ratio of Senores Pharmaceuticals is As on 22 January, 2025 | 12:21

The PB ratio of Senores Pharmaceuticals is 7.5 As on 22 January, 2025 | 12:21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23